Current diagnostic methods for tissues often rely on subjective, time-consuming processes, making them slower and less effective. CHARM is set to facilitate this process for pathologists by introducing advanced imaging technology that delivers rapid, high-resolution digital images of tissue samples.
“Although it’s important to spend time with pathologists and try to think like them, not just like an engineer or researcher”, says Renzo Vanna, our partner from the National Research Council (CNR) in Milan.
Renzo Vanna, who has a rich background in molecular medicine and extensive experience working in technological research environments, plays a crucial role in the CHARM project. His expertise helps bridge the gap between advanced technology and clinical application. Vanna’s work focuses on optimizing and validating this new imaging technology to ensure it meets the stringent requirements of clinical use.
For me, the most exciting part when I approach a clinical problem is to discuss face to face with doctors [about their] current medical needs or technological gaps.
Transcript
I’m Renzo Vanna from the National Research Council (CNR) in Milan, focusing on photonics and nanotechnology. My role in the CHARM project is to help optimize and validate our new imaging technology, with the goal of transferring it to clinical use soon.
Over the past decade, after completing my PhD in molecular medicine, I have worked in technological universities and research hospitals, closely collaborating with clinicians. During this time, I’ve been developing and optimizing innovative approaches that are not yet validated for clinical use.
One of the most exciting aspects of addressing a clinical problem for me is discussing it face-to-face with medical doctors, learning about their current needs and technological gaps. This approach aligns perfectly with my work in CHARM.
Since the inception of the project, I’ve contributed to understanding current cancer diagnosis methods. Now that the project is underway, my focus is on deepening the integration of technology with medicine. This includes understanding current procedures, standard protocols, and international guidelines.
It’s crucial to provide clinical information that fits standard clinical terminology. We need to ensure that we deliver images when expected, and provide spectroscopic signals in formats like box plots with specific statistical parameters. Understanding the language and expectations of pathologists is essential.
In light of my research field and personal goals, I believe CHARM represents a unique opportunity in Europe. It’s a chance to apply our knowledge and experience to an ambitious and exciting application.
At the heart of CHARM’s innovation is its use of coherent Raman imaging technology. This advanced method enables the generation of detailed images that can be easily analyzed by both histopathologists and AI systems.
The CHARM project not only seeks to improve diagnostic accuracy but also to alleviate the growing workload on histopathologists. By streamlining the diagnostic process and reducing the reliance on invasive procedures, CHARM promises to offer a significant advancement in patient care.